Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating CYH33 for PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM), focusing on safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pik3ca-related Overgrowth Spectrum
• Pik3ca-related Vascular Malformations

Drugs mentioned

• CYH33

Snippet

Sponsor: Haihe Biopharma Co., Ltd. | Conditions: PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM) | Phase 1, Phase 2 | Status: RECRUITING